289 related articles for article (PubMed ID: 21561437)
1. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Katara GK; Verma S; Salotra P
Br J Dermatol; 2011 Aug; 165(2):411-4. PubMed ID: 21561437
[TBL] [Abstract][Full Text] [Related]
2. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
3. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
[TBL] [Abstract][Full Text] [Related]
4. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
6. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M
Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030
[TBL] [Abstract][Full Text] [Related]
7. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
8. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis.
Mukhopadhyay D; Das NK; Roy S; Kundu S; Barbhuiya JN; Chatterjee M
J Infect Dis; 2011 Nov; 204(9):1427-36. PubMed ID: 21933878
[TBL] [Abstract][Full Text] [Related]
9. PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Ganguly S; Saha P; Chatterjee M; Roy S; Ghosh TK; Guha SK; Kundu PK; Bera DK; Basu N; Maji AK
PLoS Negl Trop Dis; 2015; 9(10):e0004138. PubMed ID: 26485704
[TBL] [Abstract][Full Text] [Related]
10. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
[TBL] [Abstract][Full Text] [Related]
11. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
12. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy.
Belay AD; Asafa Y; Mesure J; Davidson RN
Ann Trop Med Parasitol; 2006 Apr; 100(3):223-7. PubMed ID: 16630379
[TBL] [Abstract][Full Text] [Related]
13. Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial.
Sundar S; Sinha P; Jha TK; Chakravarty J; Rai M; Kumar N; Pandey K; Narain MK; Verma N; Das VN; Das P; Berman J; Arana B
Trop Med Int Health; 2013 Jan; 18(1):96-100. PubMed ID: 23136856
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
Sundar S; Singh A; Chakravarty J; Rai M
ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
[TBL] [Abstract][Full Text] [Related]
15. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
17. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Ansari NA; Jain RK; Salotra P
Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
[No Abstract] [Full Text] [Related]
18. Ambisome plus miltefosine for Indian patients with kala-azar.
Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
[TBL] [Abstract][Full Text] [Related]
19. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
Abongomera C; Battaglioli T; Adera C; Ritmeijer K
Int J Infect Dis; 2019 Apr; 81():221-224. PubMed ID: 30790722
[TBL] [Abstract][Full Text] [Related]
20. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D
Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
